0REZ Stock Chart & Stats
kr179.98
-kr3.41(-2.51%)
At close: 4:00 PM EST
kr179.98
-kr3.41(-2.51%)
Day’s Range― - ―
52-Week Rangekr133.00 - kr207.60
Previous CloseN/A
Volume906.00
Average Volume (3M)6.60K
Market Cap
kr19.21B
Enterprise Valuekr24.54K
Total Cash (Recent Filing)kr394.00M
Total Debt (Recent Filing)kr5.02B
Price to Earnings (P/E)32.2
Beta1.23
Next Earnings
Oct 21, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)4.89
Shares Outstanding117,877,460
10 Day Avg. Volume9,588
30 Day Avg. Volume6,600
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.39
Revenue Forecast (FY)kr10.89B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & ConversionConsistent high cash conversion and solid operating cash flow demonstrate durable earnings quality and internal funding capacity. This supports sustained dividend/M&A funding, deleveraging and reinvestment in services and aftermarket, improving long-term financial flexibility versus peers.
Sustained Margin ExpansionBroad-based margin improvement across quarters and segments reflects structurally better pricing, mix toward advanced products and operating leverage. Higher and expanding EBITA margins support durable profitability even if top-line cycles soften, strengthening cash generation and return on capital.
Resilient Labtech PerformanceLabtech's recurring consumables, tender wins and equipment service mix create stable, high-margin revenue streams. Strong organic growth and improving Labtech margins indicate structural demand in diagnostics/research that supports steady cash and reduces cyclicality over the medium term.
Bears Say
Meaningful Leverage RemainsAlthough leverage has improved, the company still carries notable debt relative to equity and modest coverage of obligations. Persistent leverage constrains strategic flexibility, raises sensitivity to interest costs and makes disciplined cash conversion and targeted deleveraging essential to sustain growth plans.
Working-capital & Inventory TimingVariability in receivables and higher inventories from product rollouts and delivery timing create cash-flow noise that can impede consistent deleveraging and capital allocation. Structural inventory or receivable swings weaken predictability of free cash flow and heighten funding needs during growth or M&A phases.
Reliance On M&A To Sustain GrowthManagement is leaning on bolt-on deals to drive growth, yet recent M&A added limited top-line lift while net debt rose for acquisitions and earnouts. Scaling M&A faster risks execution strain and higher leverage unless cash conversion and integration efficiencies are maintained over time.
AddLife AB News
0REZ FAQ
What was AddLife AB Class B’s price range in the past 12 months?
AddLife AB Class B lowest share price was kr133.00 and its highest was kr207.60 in the past 12 months.
What is AddLife AB Class B’s market cap?
AddLife AB Class B’s market cap is kr19.21B.
When is AddLife AB Class B’s upcoming earnings report date?
AddLife AB Class B’s upcoming earnings report date is Oct 21, 2026 which is in 84 days.
How were AddLife AB Class B’s earnings last quarter?
AddLife AB Class B released its earnings results on Jul 16, 2026. The company reported kr1.07 earnings per share for the quarter, beating the consensus estimate of kr1.053 by kr0.017.
Is AddLife AB Class B overvalued?
According to Wall Street analysts AddLife AB Class B’s price is currently Overvalued.
Does AddLife AB Class B pay dividends?
AddLife AB Class B pays a Annually dividend of kr1.5 which represents an annual dividend yield of 0.95%. See more information on AddLife AB Class B dividends here
What is AddLife AB Class B’s EPS estimate?
AddLife AB Class B’s EPS estimate is 0.88.
How many shares outstanding does AddLife AB Class B have?
AddLife AB Class B has 117,877,460 shares outstanding.
What happened to AddLife AB Class B’s price movement after its last earnings report?
AddLife AB Class B reported an EPS of kr1.07 in its last earnings report, beating expectations of kr1.053. Following the earnings report the stock price went up 2.493%.
Which hedge fund is a major shareholder of AddLife AB Class B?
Currently, no hedge funds are holding shares in GB:0REZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AddLife AB Class B
AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.
0REZ Company Deck
0REZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes broad-based positive operational momentum: margin improvement across both business areas, solid organic growth (4%) augmented by acquisitions (3%), strong Labtech performance (7% currency-adjusted growth), improving cash conversion (~100%) and Home Care emerging as a meaningful growth and margin contributor. Headwinds are mainly timing and market-specific: doctor strikes in Spain, subdued UK capital spending, higher OpEx from growth and acquisitions, inventory timing effects, and increased net debt due to M&A and dividends. Overall, the positives—sustained margin expansion, cash generation and contributing acquisitions—outweigh the transitory market and timing challenges.View all GB:0REZ earnings summaries